Engrail Therapeutics: $157 Million Raised To Develop Transformational Therapies
By Amit Chowdhry ● Mar 19, 2024
Engrail Therapeutics - a precision neuroscience company focusing on developing transformational therapies to improve patients' lives - announced the closing of an oversubscribed $157 million Series B financing round. The funding round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn, Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing investor Pivotal Life Sciences.